CXCL8 and macular retinal edema: Several inflammatory factors, including IL6, IL8, ICAM-1, MCP-1, IL1-, IL 17-E, and TNF-α, were found to be higher in the aqueous or vitreous of RVO eyes [6–8], prompting the FDA to approve an anti-inflammatory drug (Ozurdex, an intravitreal dexamethasone implant) for treating macular edema following RVO in 2009.